NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

NCT06239272 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

139

Enrollment

OTHER

Sponsor class

Conditions

Adipocytic Neoplasm
Liposarcoma
Atypical Fibroxanthoma
Angiomatoid Fibrous Histiocytoma
Myoepithelioma
Fibrosarcoma NOS
Myxofibrosarcoma
Angiosarcoma
Osteosarcoma, Extraskeletal

Interventions

PROCEDURE: Surgical resection
RADIATION: Proton beam radiation therapy
DRUG: Pazopanib
DRUG: Ifosfamide
DRUG: Doxorubicin
DRUG: Selinexor

Sponsor

St. Jude Children's Research Hospital